DPAGT1 Inhibitors
DPAGT1 inhibitors encompass a diverse set of compounds that interfere with the enzymatic function of dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (DPAGT1), a key enzyme in the N-linked glycosylation pathway. This pathway is critical for the proper folding and function of many proteins. The direct inhibitors of DPAGT1, such as tunicamycin, achieve inhibition by occupying the enzyme's catalytic site, which prevents the initial step of N-linked glycosylation from occurring. Benzyl 2-acetamido-2-deoxy-α-D-glucopyranoside imitates the natural substrate of DPAGT1, competing for binding at the active site and thereby decreasing enzyme activity. Similarly, ribostamycin and deoxynojirimycin interfere with DPAGT1 by mimicking its substrates, effectively acting as competitive inhibitors. These compounds directly block the enzymatic action of DPAGT1, preventing the transfer of sugar moieties that are essential for glycoprotein synthesis.
In contrast, indirect inhibitors modulate the activity of DPAGT1 by influencing its cellular environment or related pathways. Decylubiquinone, by affecting the electron transfer chain, indirectly modulates the cellular conditions that are necessary for optimal DPAGT1 activity. Bacitracin interacts with metal ions that are cofactors for DPAGT1, impairing the enzyme's functionality. Compounds like EerI and swainsonine exert their inhibitory effects by disrupting protein processing pathways in the endoplasmic reticulum (ER) and the Golgi apparatus, respectively. This disruption can lead to increased unfolded protein response, which may inadvertently affect the stability and efficiency of DPAGT1. Emodin alters cellular signaling pathways, which can have downstream effects on the regulation of various enzymes including DPAGT1. Brefeldin A interferes with the structure and function of the Golgi apparatus, where DPAGT1 exerts its action, leading to a reduction in the enzyme's efficacy. Chloroquine, through its ability to alter the pH within intracellular compartments, can create an environment that is not conducive to the activity of DPAGT1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits DPAGT1 by blocking the enzyme's catalytic site, preventing the transfer of N-acetylglucosamine to dolichol phosphate, which is a crucial step in N-linked glycosylation. | ||||||
4-(Hydroxymethyl)benzoic acid | 3006-96-0 | sc-214213 sc-214213A | 1 g 10 g | $58.00 $417.00 | ||
Decylubiquinone, an analog of coenzyme Q10, can interfere with the electron transfer chain and create an unfavorable cellular environment for DPAGT1 activity, indirectly reducing its functional capacity. | ||||||
Bacitracin | 1405-87-4 | sc-252399 | 5 g | $89.00 | 1 | |
Bacitracin is known to inhibit a range of glycosyltransferases, and it can bind to bivalent metal ions in the active site of DPAGT1, interfering with its enzymatic activity. | ||||||
Dimethyloxaloylglycine (DMOG) | 89464-63-1 | sc-200755 sc-200755A sc-200755B sc-200755C | 10 mg 50 mg 100 mg 500 mg | $84.00 $301.00 $374.00 $779.00 | 25 | |
EerI disrupts the ERAD pathway and can lead to the accumulation of misfolded glycoproteins, indirectly affecting DPAGT1 by increasing the stress on the endoplasmic reticulum, where DPAGT1 is localized. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin can inhibit various glycosyltransferases and, through structural mimicry of monosaccharides, may bind to and inhibit DPAGT1, preventing the processing of its glycoprotein substrates. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine, an indolizidine alkaloid, inhibits glycosidases but can also affect glycosyltransferases like DPAGT1 by competitive inhibition, due to its structural similarity to monosaccharides. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $105.00 $214.00 $6255.00 | 2 | |
Emodin is a tyrosine kinase inhibitor that can indirectly affect DPAGT1 by altering signaling pathways that regulate glycosylation, potentially reducing its enzymatic activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure and function, leading to a cascade of effects that can reduce the efficacy of enzymes like DPAGT1 involved in glycoprotein synthesis. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, primarily known as an antimalarial drug, can elevate the pH of intracellular vesicles and indirectly affect the enzymatic activity of DPAGT1 by altering the optimum pH necessary for its function. | ||||||